AOD-9604: the tail of growth hormone, and not the hormone

AOD-9604 is a short peptide built from the tail of human growth hormone. The parent idea, from Frank Ng and colleagues in Melbourne, was that a fragment around residues 177 to 191 of the 191-amino-acid hormone could push fat cells to release fat without doing the rest of what growth hormone does. AOD-9604 is that region with a tyrosine added at the front, so you will also see it written Tyr-hGH 177–191. It does not bind and activate the growth-hormone receptor the way the full 191 does. It does not raise IGF-1. It is not a secretagogue, so it does not ask the pituitary for a pulse. If a product is raising IGF-1, it is not behaving as this fragment. It is behaving as growth hormone, or as something else entirely.

In short. AOD-9604 is a piece of the end of growth hormone, with one extra amino acid. It was meant to touch fat without being growth hormone. It does not raise IGF-1. If IGF-1 rises, you do not have this fragment.

The animal work is why the fragment was taken seriously. In obese rodents the peptide increased lipolysis and reduced fat mass, and it did so without a clear IGF-1 rise and without the hyperglycaemia people worry about with intact growth hormone. A rodent fat pad is not a person. Metabolic Pharmaceuticals took AOD-9604 into human obesity trials on the back of that story. The programme did not produce an approved drug. Later sports-prohibition listings put the fragment on banned lists because of the growth-hormone family resemblance, not because a physique trial had shown a result. A ban is a rule about a class. It is not a clinical outcome.

In short. Obese animals lost fat in the early papers without an IGF-1 rise. The human obesity programme did not become a medicine. Being banned in sport is a rule, not a published result in athletes.

Full somatropin is 191 residues, one receptor, JAK2 and STAT5, IGF-1 from the liver, and a real medicine for growth-hormone deficiency with a real list of costs at abuse doses. Tesamorelin and CJC without DAC ask the pituitary to release that hormone. MK-677 asks it all day through the ghrelin receptor. Semaglutide and tirzepatide cut appetite through incretin receptors and have the trial numbers to show it. AOD-9604 does none of those jobs. The commercial sentence that it is 'HGH without the side effects' keeps the surname and loses the receptor. Side effects of growth hormone come from being growth hormone. A fragment that does not turn the receptor on cannot offer the effects either. You do not get the IGF-1, the nitrogen retention, or the water, because you did not start the pathway.

In short. It is not HGH, not CJC, not MK-677, and not a GLP-1 drug. Those work by receptors this fragment does not touch. Skipping the side effects also skips the action.

There is a separate, thinner literature on cartilage and on the local injection of the fragment in joint models. It is not a reason to rename the peptide a repair drug, and it is not BPC-157 or TB-500, which are different sequences with different papers. Identity is the first kindness. Sixteen residues from the tail of growth hormone, a tyrosine on the front, no GHR activation, no IGF-1. Anyone selling a vial that 'acts like HGH on fat only' is describing the hope of the 1990s rodent work, not the medicine that failed to appear, and not the 191-residue hormone sitting on a different page of this journal.

In short. A few joint studies exist and do not turn it into a repair peptide. The honest description is a 16-residue tail of growth hormone that does not turn growth hormone's receptor on.